Sacituzumab (hRS7) is an antibody inhibitor and a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2), serving as a component of the antibody-drug conjugate sacituzumab govitecan, used for research and treatment of TROP2-high-expressing tumors such as triple-negative breast cancer.

Methods: The in vitro activity of Sacituzumab (hRS7 IgG) was verified by cell viability assays and antibody-dependent cell-mediated cytotoxicity (ADCC) experiments. Trop-2-positive cervical cancer cells (CVX8, ADX3) and negative cells (ADX2) were incubated with 2 μg/mL Sacituzumab for 72 hours, respectively.
Results: Sacituzumab showed no direct cytotoxicity in the absence of effector cells, but could mediate significant ADCC by peripheral blood lymphocytes against Trop-2-positive cells.[1]
Methods: Trop-2-positive cervical cancer cells (CVX8, ADX3) and negative cells (ADX2) were incubated with 2 μg/mL Sacituzumab for 72 hours.
Results: Its IC₅₀ was 55–68 times higher than that of the ADC, with no direct cytotoxicity in the absence of effector cells; however, it could mediate significant ADCC by peripheral blood lymphocytes against Trop-2-positive cells (57.9%±5.5%).[2]

Methods: MDA-MB-468 triple-negative breast cancer cells were inoculated into SCID/NCr mice. Sacituzumab (25 mg/kg, dissolved in physiological saline) was administered by intravenous injection twice weekly for 3 weeks.
Results: Tumor burden was reduced in the treatment group, all mice survived to 60 days, showing significant difference compared with the vehicle control group (P < 0.0001). [3]

HEK293

Human

Immobilized Human TROP-2 Protein (His) (TMPY-01262) at 2 μg/mL (100 μL/well) can bind Sacituzumab. The EC50 is 1.04 ng/mL.

Monoclonal

Unconjugated